Kishnani P, Byrne B, Claeys K, Diaz-Manera J, Dimachkie M, Kushlaf H
J Patient Rep Outcomes. 2024; 8(1):132.
PMID: 39535661
PMC: 11561219.
DOI: 10.1186/s41687-024-00805-w.
Truninger M, Werner H, Landolt M, Hahn A, Hennermann J, Lagler F
Orphanet J Rare Dis. 2024; 19(1):358.
PMID: 39342352
PMC: 11438293.
DOI: 10.1186/s13023-024-03368-7.
Tan L, Zschuntzsch J, Meyer S, Stobbe A, Bruex H, Regensburger A
Nat Commun. 2024; 15(1):7843.
PMID: 39245687
PMC: 11381542.
DOI: 10.1038/s41467-024-52143-6.
van Kooten H, Horton M, Wenninger S, Babacic H, Schoser B, Lefeuvre C
Eur J Neurol. 2024; 31(12):e16397.
PMID: 39205420
PMC: 11554865.
DOI: 10.1111/ene.16397.
Retailleau E, Lefeuvre C, Antonio M, Bouhour F, Tard C, Salort-Campana E
Eur J Neurol. 2024; 31(10):e16428.
PMID: 39109844
PMC: 11414798.
DOI: 10.1111/ene.16428.
The PompeQoL questionnaire: Development and validation of a new measure for children and adolescents with Pompe disease.
Truninger M, Werner H, Landolt M, Hahn A, Hennermann J, Lagler F
J Inherit Metab Dis. 2024; 47(6):1348-1362.
PMID: 38979754
PMC: 11586600.
DOI: 10.1002/jimd.12777.
Validation of the Patient-Reported Outcomes Measurement Information System (PROMIS) physical function questionnaire in late-onset Pompe disease using PROPEL phase 3 data.
Kishnani P, Shohet S, Raza S, Hummel N, Castelli J, Das S
J Patient Rep Outcomes. 2024; 8(1):13.
PMID: 38294575
PMC: 10830974.
DOI: 10.1186/s41687-024-00686-z.
Measurement Properties of 2 Novel PROs, the Pompe Disease Symptom Scale and Pompe Disease Impact Scale, in the COMET Study.
Dimachkie M, Kishnani P, Ivanescu C, Flore G, Gwaltney C, van der Beek N
Neurol Clin Pract. 2023; 13(5):e200181.
PMID: 37559825
PMC: 10409572.
DOI: 10.1212/CPJ.0000000000200181.
Quality of Life with Late-Onset Pompe Disease: Qualitative Interviews and General Public Utility Estimation in the United Kingdom.
Hubig L, Sussex A, MacCulloch A, Hughes D, Graham R, Morris L
J Health Econ Outcomes Res. 2023; 10(1):41-50.
PMID: 36883056
PMC: 9985911.
DOI: 10.36469/001c.68157.
Measurement properties of the Swedish clinical outcomes in routine evaluation outcome measures (CORE-OM): Rasch analysis and short version for depressed and anxious out-patients in a multicultural area.
Danielsson L, Elfstrom M, Galan Henche J, Melin J
Health Qual Life Outcomes. 2022; 20(1):30.
PMID: 35183201
PMC: 8858495.
DOI: 10.1186/s12955-022-01937-7.
Six-Minute Walk Distance Is a Useful Outcome Measure to Detect Motor Decline in Treated Late-Onset Pompe Disease Patients.
Claeys K, DHondt A, Fache L, Peers K, Depuydt C
Cells. 2022; 11(3).
PMID: 35159144
PMC: 8834389.
DOI: 10.3390/cells11030334.
Qualitative interviews to improve patient-reported outcome measures in late-onset Pompe disease: the patient perspective.
Hamed A, Haack K, Gwaltney C, Baranowski E, Stewart A, Krupnick R
Orphanet J Rare Dis. 2021; 16(1):428.
PMID: 34641935
PMC: 8513325.
DOI: 10.1186/s13023-021-02067-x.
Development and Construct Validity of the Work Instability Scale for People With Common Mental Disorders in a Sample of Depressed and Anxious Workers: A Rasch Analysis.
Danielsson L, Fornazar R, Holmgren K, Lundgren Nilsson A, Hensing G
Rehabil Process Outcome. 2021; 9:1179572720936664.
PMID: 34497467
PMC: 8282151.
DOI: 10.1177/1179572720936664.
Positive association between physical outcomes and patient-reported outcomes in late-onset Pompe disease: a cross sectional study.
Yuan M, Andrinopoulou E, Kruijshaar M, Lika A, Harlaar L, van der Ploeg A
Orphanet J Rare Dis. 2020; 15(1):232.
PMID: 32883321
PMC: 7469279.
DOI: 10.1186/s13023-020-01469-7.
Late-onset Pompe disease (LOPD) in Belgium: clinical characteristics and outcome measures.
Vanherpe P, Fieuws S, DHondt A, Bleyenheuft C, Demaerel P, De Bleecker J
Orphanet J Rare Dis. 2020; 15(1):83.
PMID: 32248831
PMC: 7133011.
DOI: 10.1186/s13023-020-01353-4.
Large variation in effects during 10 years of enzyme therapy in adults with Pompe disease.
Harlaar L, Hogrel J, Perniconi B, Kruijshaar M, Rizopoulos D, Taouagh N
Neurology. 2019; 93(19):e1756-e1767.
PMID: 31619483
PMC: 6946483.
DOI: 10.1212/WNL.0000000000008441.
.
Jones H, Kuchibhatla M, Crisp K, Hobson Webb L, Case L, Batten M
Mol Genet Metab. 2019; 127(4):346-354.
PMID: 31303277
PMC: 6717661.
DOI: 10.1016/j.ymgme.2019.05.001.
The role of rehabilitation in the management of late-onset Pompe disease: a narrative review of the level of evidence.
Iolascon G, Vitacca M, Carraro E, Chisari C, Fiore P, Messina S
Acta Myol. 2019; 37(4):241-251.
PMID: 30944902
PMC: 6416696.
The ACE I/D polymorphism does not explain heterogeneity of natural course and response to enzyme replacement therapy in Pompe disease.
Kuperus E, van der Meijden J, In t Groen S, Kroos M, Hoogeveen-Westerveld M, Rizopoulos D
PLoS One. 2018; 13(12):e0208854.
PMID: 30532252
PMC: 6285976.
DOI: 10.1371/journal.pone.0208854.
Patient reported outcome measures in rare diseases: a narrative review.
Slade A, Isa F, Kyte D, Pankhurst T, Kerecuk L, Ferguson J
Orphanet J Rare Dis. 2018; 13(1):61.
PMID: 29688860
PMC: 5914068.
DOI: 10.1186/s13023-018-0810-x.